Ritlecitinib (malonate)


CAS No. : 2140301-97-7

(Synonyms: PF-06651600 (malonate))

2140301-97-7
Price and Availability of CAS No. : 2140301-97-7
Size Price Stock
5mg $267 Get quote
10mg $428 Get quote
50 mg Get quote
100 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-100754A
M.Wt: 389.41
Formula: C18H23N5O5
Purity: >98 %
Solubility: 10 mM in DMSO
Introduction of 2140301-97-7 :

Ritlecitinib (PF-06651600) malonate is a highly selective, orally active, irreversible covalent JAK3 inhibitor (IC50=33 nM) without inhibitory activity towards JAK1, JAK2, and TYK2 (IC50 >10 μ M). Ritlecitinib malonate rapidly inactivates the JAK3 kinase, and blocks signaling and downstream STAT phosphorylation mediated by common gamma chain cytokines such as IL-2 and IL-15. Ritlecitinib malonate can inhibit Th1/Th17 cell differentiation and function, and effectively suppress preclinical animal models such as alopecia areata, adjuvant-induced arthritis (AIA), and experimental autoimmune encephalomyelitis (EAE)[1][2][3]. In Vitro:Ritlecitinib malonate inhibits IL-15 in peripheral blood mononuclear cells (PBMCs) and heparin treated human whole blood (HWB) with IC50 of 51 nM and 197 nM, respectively[1].
Ritlecitinib malonate inhibits the phosphorylation of STAT proteins mediated by IL-2 (STAT5), IL-4 (STAT6), IL-7 (STAT5), IL-15 (STAT5), and IL-21 (STAT3) at concentrations of 244 nM, 340 nM, 407 nM, 266 nM, and 355 nM (IC50), respectively[2].
Ritlecitinib malonate (30 nM, 167 nM; 5 days, 6 days) inhibits cell differentiation in Th1 and Th17 cell differentiation inhibition experiments for 5 days under Th1 conditions and 6 days under Th17 conditions, respectively[2].
In Vivo:Ritlecitinib (3, 10, 30 mg/kg; oral; once daily; 7 days) malonate reduces joint swelling and improves disease severity in a dose-dependent manner in the Sprague-Dawley rat adjuvant-induced arthritis (AIA) model[2].
Ritlecitinib (30, 100 mg/kg (reversal); 20, 60 mg/kg (prevention); oral; once daily) malonate reduces disease severity in the mouse experimental autoimmune encephalomyelitis (EAE) model[2].
Ritlecitinib (30 mg/kg; oral; once daily; 4 weeks) malonate can prevent the occurrence of alopecia areata in the C3H/HeJ mouse skin transplantation alopecia areata prevention model; Ritlecitinib (30 mg/kg; oral; once daily; 12 weeks) malonate can reverse the symptoms of alopecia areata, promote hair regeneration and reduce skin inflammation in the C3H/HeJ mouse alopecia areata model[3].

Your information is safe with us.